Dosage Forms. Suspension for Intramuscular Injection: For Adults, available in combination with tetanus and diphtheria toxoids (Tdap); for Children, available in combination with tetanus and diphtheria toxoids (DTaP), and in combination with other pediatric vaccines
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of pertussis: Children, all infants at age 2, 4, 6, and 12-15 mo, and a fifth dose at age 4-6 y, as primary series of DTaP; Adults, at age 11-12 y, Tdap
1. Prevention of pertussis during pregnancy: Pregnant females, preferably during 27-36 wk gestation of each pregnancy, Tdap.
Drug Characteristics: Pertussis Vaccine, Acellular
Medication Safety Issues: Pertussis Vaccine, Acellular
Drug Interactions: Pertussis Vaccine, Acellular
Adverse Reactions: Pertussis Vaccine, Acellular
Efficacy Monitoring Parameters. Prevention of pertussis.
Toxicity Monitoring Parameters. Monitor for syncope for 15 min after injection.
Key Patient Counseling Points. Return to provider for each dose in the series.
Clinical Pearls. Use the same brand of vaccine to complete the entire series, if possible. Adacel not for use in children <11 y of age. Daptacel not for use in children <6 wk or >6 y of age. Use caution to avoid mistaking Tdap and DTaP products.